Skip to main content

MINI REVIEW article

Front. Psychiatry
Sec. Psychological Therapy and Psychosomatics
Volume 15 - 2024 | doi: 10.3389/fpsyt.2024.1429373
This article is part of the Research Topic Psychedelic-Assisted Psychotherapies: From Clinical Trials to Credibility View all articles

A Narrative Exploration of Psilocybin's Potential in Mental Health

Provisionally accepted
Huitae Min Huitae Min 1Soon-Yeong Park Soon-Yeong Park 2Jisu Park Jisu Park 1,3Seongsu Na Seongsu Na 1,3Hoe-Suk Lee Hoe-Suk Lee 3Taejung Kim Taejung Kim 1,4Jungyeob Ham Jungyeob Ham 1,2,4*Young-Tae Park Young-Tae Park 1,4*
  • 1 Natural Products Research Center, Korea Institute of Science and Technology, Gangneung, Republic of Korea
  • 2 NeoCannBio Co., Ltd., Seoul, Republic of Korea
  • 3 Department of Biochemical Engineering, Gangneung–Wonju National University, Gangneung, Gangwon, Republic of Korea
  • 4 Division of Bio-Medical Science and Technology, University of Science and Technology (UST), Daejeon, Republic of Korea

The final, formatted version of the article will be published soon.

    Psilocybin, a psychoactive substance, has recently garnered attention for its high therapeutic potential in psychiatry. In this study, we investigated the multifaceted aspects of psilocybin, highlighting its chemical properties, mechanisms of action, and burgeoning role in psychiatric treatment. Furthermore, we examined the clinical applications and potential therapeutic benefits of psilocybin in the treatment of various mental health disorders, supported by accumulating clinical evidence. This review aims to deepen our understanding of the clinical impact of psilocybin, elucidate its therapeutic value, and propose directions for future research, thereby paving the way for its integration into mainstream psychiatric treatments. Psilocybin has been shown to be safe in clinical trials with manageable side effects. However, additional safety measures are required after this discussion, including dosing protocols, patient monitoring, and distress management strategies.

    Keywords: psilocybin, Psychoactive, Psychiatry, Mental Health Disorders, dosing

    Received: 08 May 2024; Accepted: 04 Oct 2024.

    Copyright: © 2024 Min, Park, Park, Na, Lee, Kim, Ham and Park. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jungyeob Ham, Natural Products Research Center, Korea Institute of Science and Technology, Gangneung, Republic of Korea
    Young-Tae Park, Natural Products Research Center, Korea Institute of Science and Technology, Gangneung, Republic of Korea

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.